Segment and Geographic Information - Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Total revenue	$ 165,948	$ 132,735	$ 492,715	$ 417,931
Amortization of other intangible assets	12,200	7,600	23,400	36,100
Purchase accounting impact on inventory	2,956		8,737
Restructuring charges	812	25	3,773	319
Contingent consideration - fair value adjustments	(1,404)		(18,549)	600
Tariff adjustment				(486)
Total operating (loss) income	(15,836)	(5,073)	(56,498)	(10,106)
Interest income	11,347	6,822	32,406	9,933
Interest expense		(2,101)		(4,111)
Loss on extinguishment of debt				(632)
Other, net	819	630	(704)	(1,617)
(Loss) income before income taxes	(3,670)	278	(24,796)	(6,533)
Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	4,656	1,810	13,725	5,424
Acquired Intangible Assets
Segment Reporting Information [Line Items]
Amortization of other intangible assets	7,522	5,745	22,403	18,064
Life Sciences Products
Segment Reporting Information [Line Items]
Total revenue	74,571	47,369	223,091	150,861
Total operating (loss) income	(4,878)	1,965	(25,077)	11,173
Life Sciences Services
Segment Reporting Information [Line Items]
Total revenue	91,377	85,366	269,624	267,070
Total operating (loss) income	(3,813)	697	(13,302)	10,759
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	165,948	132,735	492,715	417,931
Total operating (loss) income	(8,691)	2,662	(38,379)	21,932
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Other unallocated corporate expense	$ (7,397)	$ 155	$ (11,970)	$ 8,717